PDF(Pubmed)
Abstract：
This study investigates the roles of RUVBL1 and HIF1A in ccRCC development and explores their clinical significance as prognostic biomarkers. mRNA and protein expressions were analyzed using TCGA data and an institutional tissue cohort, respectively. Correlations with clinicopathological parameters and patient outcomes were assessed. TCGA data revealed significantly elevated RUVBL1 mRNA expression in ccRCC tissues, associated with advanced histological grade, T stage, lymph node metastasis, and clinical stage. High RUVBL1 mRNA expression correlated with inferior overall survival and served as an adverse prognostic factor. Similarly, HIF1A mRNA expression was significantly higher in ccRCC tissues, correlating with worse overall survival and acting as an adverse prognostic factor for treatment outcomes. Simultaneous evaluation of RUVBL1 and HIF1A mRNA expression demonstrated enhanced prognostic capacity, surpassing the predictive power of individual markers. Immunohistochemical staining confirmed substantial upregulation of both RUVBL1 and HIF-1α proteins in ccRCC tissues. Furthermore, high expression of both RUVBL1 and HIF-1α proteins was significantly associated with shorter patient survival time. Our findings underscore the significance of RUVBL1 and HIF-1α as potential prognostic markers in ccRCC, paving the way for further research to translate these insights into clinically relevant applications.
摘要：
这项研究调查了RUVBL1和HIF1A在ccRCC发展中的作用，并探讨了它们作为预后生物标志物的临床意义。使用TCGA数据和机构组织队列分析mRNA和蛋白质表达，分别。评估与临床病理参数和患者预后的相关性。TCGA数据显示ccRCC组织中RUVBL1mRNA表达显著升高，与高级组织学等级相关，T级,淋巴结转移,和临床分期。高RUVBL1mRNA表达与低总生存率相关，并作为不良预后因素。同样，HIF1AmRNA在ccRCC组织中表达显著增高,与较差的总生存期相关，并作为治疗结局的不良预后因素。同时评估RUVBL1和HIF1AmRNA表达显示增强的预后能力，超越个体标记的预测能力。免疫组织化学染色证实ccRCC组织中RUVBL1和HIF-1α蛋白均显著上调。此外，RUVBL1和HIF-1α蛋白的高表达与较短的患者生存时间显著相关.我们的发现强调了RUVBL1和HIF-1α作为ccRCC潜在预后标志物的意义。为进一步研究铺平道路，将这些见解转化为临床相关应用。
